MedPath

UREA

Urea 40% Cream

Approved
Approval ID

6774a5ef-9bb0-4e7a-e053-2a91aa0af47f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Mar 6, 2024

Manufacturers
FDA

BioComp Pharma, Inc.

DUNS: 829249718

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

UREA

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code44523-617
Product Classification
G
Generic Name
UREA
Product Specifications
Route of AdministrationTOPICAL
Effective DateMarch 6, 2024
FDA Product Classification

INGREDIENTS (11)

CARBOMER INTERPOLYMER TYPE A (55000 CPS)Inactive
Code: 59TL3WG5CO
Classification: IACT
CETYL ALCOHOLInactive
Code: 936JST6JCN
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
GLYCERYL MONOSTEARATEInactive
Code: 230OU9XXE4
Classification: IACT
DIMETHYL ISOSORBIDEInactive
Code: SA6A6V432S
Classification: IACT
PETROLATUMInactive
Code: 4T6H12BN9U
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
XANTHAN GUMInactive
Code: TTV12P4NEE
Classification: IACT
UREAActive
Quantity: 400 mg in 1 g
Code: 8W8T17847W
Classification: ACTIB
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
MINERAL OILInactive
Code: T5L8T28FGP
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 2/1/2018

LabelLabelLabelCarton

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 3/15/2018

INDICATIONS:

For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails.

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 3/15/2018

CONTRAINDICATIONS:

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product.

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 3/15/2018

ADVERSE REACTIONS:

Transient stinging, burning, itching or irritation may occur and normally disappear upon discontinuing the use of this product.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 3/15/2018

Rx Only

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 3/15/2018

CLINICAL PHARMACOLOGY:

Urea gently dissolves the intercellular matrix which results in loosening the horny layer of skin and shedding scaly skin at regular intervals, thereby softening hyperkeratotic areas of the skin.

**Pharmacokinetics:**The mechanism of action of topically applied urea is not yet known.

DESCRIPTION SECTION

LOINC: 34089-3Updated: 3/15/2018

DESCRIPTION:

Each gram contains 400 mg of urea in a vehicle consisting of: carbomer, cetyl alcohol, dimethyl isosorbide, glyceryl stearate, mineral oil, petrolatum, propylene glycol, purified water, sodium hydroxide and xanthan gum.

Urea is a diamide of carbonic acid with the following chemical structure:

structure.jpg

WARNINGS SECTION

LOINC: 34071-1Updated: 3/15/2018

WARNING:

KEEP OUT OF REACH OF CHILDREN.

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 3/15/2018

PRECAUTIONS:

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

**General:**This product is to be used as directed by a physician and should not be used to treat any condition other than that for which it was prescribed. If redness or irritation occurs, discontinue use and consult a physician.

**Information for Patients:**Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. Avoid contact with eyes, lips and mucous membranes.

**Carcinogenesis, Mutagenesis and Impairment of Fertility:**Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed.

**Pregnancy:**Category C.Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

**Nursing Mothers:**It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 3/15/2018

DOSAGE AND ADMINISTRATION:

Apply to affected area(s) twice per day or as directed by a physician. Rub in until completely absorbed.

Apply to diseased or damaged nail(s) twice per day, or as directed by a physician.

STORAGE AND HANDLING SECTION

LOINC: 44425-7Updated: 3/15/2018

STORAGE:

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

**NOTICE:**Protect from freezing and excessive heat. Keep bottle tightly closed.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 3/15/2018

HOW SUPPLIED:

1 oz. (28.35 g) bottles,NDC44523-617-01
3 oz. (85 g) bottles,NDC44523-617-03
7 oz. (198.4 g) bottles,NDC44523-617-07

To reporta serious adverse event or obtain product information, call (866) 762-2365.

Manufactured for:
BIOCOMP PHARMA, INC.
San Antonio, TX 78230 1355
827650 R0218

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

UREA - FDA Drug Approval Details